Anixa Biosciences is trading 5.4% higher at $2.94 in pre-market, alongside broader biotechnology-sector strength. - XBI was up 2.61% pre-market. - No new company-specific announcement or earnings release dated September 22–23 was identified. - The latest company release was a September 21 Australian breast-cancer-vaccine patent announcement; available company materials do not explicitly connect it to the September 23 move.